Ganciclovir-Resistant Cytomegalovirus in Organ and Stem Cell Transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ReCySOHT study is a multicenter, retrospective, observational case-control analysis. It aims to identify risk factors and incidence of ganciclovir-resistant or refractory CMV infection in SOT and HSCT patients. By examining past cases and controls, the study seeks to inform future prevention and management strategies for this difficult CMV complication. The research will rely on existing clinical and laboratory data to characterize patterns related to treatment resistance. Interventions are not specified within the study design.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
* Ability to understand the purpose of the study and provide signed and dated informed consent

Exclusion Criteria:

* Lack of clinical and/or laboratory data regarding the type of CMV event
* Lack of the serological mismatch at transplantation
* Lack of the type of SOT or HSCT
* Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Bologna, Italy Recruiting
• Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT)
  Palermo, Palermo, Italy Recruiting
• Policlinico di Milano
  Milan, Italy Recruiting
• Azienda Ospedaliero-Universitaria di Modena
  Modena, Italy Recruiting
• AOU Città della salute e della scienza
  Torino, Italy Recruiting
• Hospital Clinic
  Barcelona, Spain Recruiting

Study contacts

• Principal investigator: Renato Pascale, MD — Irccs Aoubo
• Study coordinator: Renato Pascale, MD
• Email: renato.pascale@aosp.bo.it
• Phone: +390512144350

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Family-donor viral CTLs plus standard care vs standard care alone for refractory ADV or CMV infection after stem cell transplant

  This study tests whether using family-donor virus-specific CTLs in addition to usual treatment helps children, teens, and young adults with hard-to-treat CMV or adenovirus infections after a stem cell transplant.

  Recruiting Phase 3 New York Medical College · Valhalla, New York and 1 other locations · NCT07225972

• CMV-specific immunoglobulin to prevent CMV problems in children getting allogeneic stem cell transplants

  Doctors will try giving CMV-specific immunoglobulin to children having allogeneic stem cell transplants to prevent CMV reactivation and related transplant complications.

  Recruiting University of Pisa · Trieste · NCT07013370

• R-MVST cell therapy for viral infections in children and young adults

  This will try giving rapidly generated virus-specific T cells (R-MVST) to children and young adults whose weakened immune systems have recurrent or treatment-resistant infections with EBV, CMV, adenovirus, or BK virus.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06926894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.